EyeCRO scientists contribute to paper published in Biology
Therapeutic Effects of Fenofibrate Nano-Emulsion Eye Drops on Retinal Vascular Leakage and Neovascularization
Similar Posts
Bio Matters: Family influences led eyecro’s executive into scientific research
Rafal Farjo, Ph.D. is chief operating officer of both eyecro and Charlesson, which are involved in research to advance treatments for eye disease such as age-related macular degeneration, diabetic retinopathy and ocular inflammation. Far from resisting his family’s interest in all things STEM — science, technology, engineering and math — Farjo embraced it. “I loved it, and…
EyeCRO Contributes to Evaluation of SPVN06 Gene Therapy
A new Gene Therapy publication details the safety and biodistribution assessment of SPVN06, a mutation-independent gene therapy in development for rod–cone dystrophies (RCDs). These inherited retinal disorders are a leading cause of vision loss and can result from mutations in more than 100 different genes, which makes developing broadly applicable treatments challenging. SPVN06 is an…
eyecro COO Dr. Rafal Farjo to Chair Upcoming Conference
The 6th Ocular Diseases & Drug Discovery Conference is taking place on March 20-21, 2014 in San Diego, CA. The conference continues to offer presentations on novel and innovative therapeutics in ocular drug development and discovery. This forum allows for excellent networking, the exchange of ideas, and sharing of challenges; all with a united common…
Partnership Aims to Take Advantage of Preclinical Ophthalmology Developments
Rafal Farjo, PhD, COO of eyecro, told Outsourcing-pharma.com that the “demand for ophthalmology studies is increasing. Many research scientists are uncovering new mechanisms and targets for ophthalmic disease, it is also becoming apparent that there is pathology in common with many other clinical indications. eyecro specializes in ophthalmic studies of preclinical efficacy, pharmacokinetics, toxicology, and…
eyecro and NeuMedics announce collaboration to utilize MiDROPS™ technology for the development of NM108
Oklahoma City, OK, and Seattle, WA; (May 4, 2015) – eyecro LLC and NeuMedics Inc., today announced the formation of a collaboration to facilitate development of NM108, a first-in-class small molecule to treat a number of ophthalmic disorders that lead to blindness, including Diabetic Retinopathy. The collaboration grants NeuMedics full access to the MiDROPS™ formulation…
Groundbreaking Research Published in Collaboration with the National Eye Institute
We are thrilled to announce the publication of our latest research in eLife. This milestone represents an inspiring collaboration between EyeCRO and the esteemed laboratory of Dr. Anand Swaroop at the National Eye Institute. Our partnership exemplifies how teamwork and shared vision can advance the frontiers of science and medicine, particularly in the development of…
